首页> 外文OA文献 >Clinical efficacy of intravitreal aflibercept versus panretinal photocoagulation for best corrected visual acuity in patients with proliferative diabetic retinopathy at 52 weeks (CLARITY):A multicentre, single-blinded, randomised, controlled, phase 2b, non-inferiority trial

【2h】

Clinical efficacy of intravitreal aflibercept versus panretinal photocoagulation for best corrected visual acuity in patients with proliferative diabetic retinopathy at 52 weeks (CLARITY):A multicentre, single-blinded, randomised, controlled, phase 2b, non-inferiority trial

机译：玻璃体腔注射阿柏西普与全视网膜光凝治疗52周增生性糖尿病视网膜病变患者的最佳矫正视力的临床疗效（CLARITY）：一项多中心，单盲，随机，对照，2b期非劣效性试验

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

作者
Sivaprasad Sobha; Prevost A. Toby; Vasconcelos Joana C.; Riddell Amy; Murphy Caroline; Kelly Joanna; Bainbridge James; Tudor-Edwards Rhiannon; Hopkins David; Hykin Philip;
展开▼
作者单位

展开▼
年度 2017
总页数
原文格式 PDF
正文语种 eng
中图分类

相似文献

外文文献
中文文献

1. Clinical efficacy of intravitreal aflibercept versus panretinal photocoagulation for best corrected visual acuity in patients with proliferative diabetic retinopathy at 52 weeks (CLARITY): a multicentre, single-blinded, randomised, controlled, phase 2b, non-inferiority trial [J] . Sivaprasad Sobha, Prevost A. Toby, Vasconcelos Joana C., The Lancet . 2017,第10085期

机译：52周（透明度）增殖糖尿病视网膜病变术治疗术治疗术治疗最佳矫正视力的临床疗效与Panretinal光凝患者（清楚）：多期，单盲，随机，受控，相2B，非劣级试验
2. Structural and functional assessment of macula in patients with high-risk Proliferative diabetic retinopathy submitted to Panretinal photocoagulation and associated Intravitreal Bevacizumab injections: A comparative, Randomised, controlled trial [J] . PretiR.C., VasquezRamirezL.M., RibeiroMonteiroM.L., Ophthalmologica: International Journal of Ophthalmology=Journal International d'Ophtalmologie . 2013,第1期

机译：接受全视网膜光凝和相关玻璃体内贝伐单抗注射治疗的高危增生性糖尿病视网膜病变患者黄斑的结构和功能评估：一项比较，随机，对照试验
3. Contrast sensitivity evaluation in high risk proliferative diabetic retinopathy treated with panretinal photocoagulation associated or not with intravitreal bevacizumab injections: A randomised clinical trial [J] . PretiR.C., RamirezL.M.V., MonteiroM.L.R., British journal of ophthalmology . 2013,第7期

机译：玻璃体腔注射贝伐单抗联合或不联合玻璃体腔光凝治疗的高风险增生性糖尿病视网膜病变的对比敏感性评估：一项随机临床试验
4. Clinical efficacy and mechanistic evaluation of aflibercept for proliferative diabetic retinopathy (acronym CLARITY): a multicentre phase IIb randomised active-controlled clinical trial [O] . Sobha Sivaprasad, A Toby Prevost, James Bainbridge, 2015

机译：阿柏西普治疗增生性糖尿病视网膜病变的临床疗效和机理评估（缩写CLARITY）：一项多中心IIb期随机对照研究
5. Clinical efficacy of intravitreal aflibercept versus panretinal photocoagulation for best corrected visual acuity in patients with proliferative diabetic retinopathy at 52 weeks (CLARITY) a multicentre, single-blinded, randomised, controlled, phase 2b, non-inferiority trial [O] . Sivaprasad, Sobha, Prevost, A Toby, Vasconcelos, Joana C, 2017

机译：玻璃体腔注射阿柏西普与全视网膜光凝治疗52周增生性糖尿病视网膜病变患者（CLARITY）的最佳矫正视力的临床疗效（CLARITY）多中心，单盲，随机，对照，2b期，非劣效性试验

Clinical efficacy of intravitreal aflibercept versus panretinal photocoagulation for best corrected visual acuity in patients with proliferative diabetic retinopathy at 52 weeks (CLARITY):A multicentre, single-blinded, randomised, controlled, phase 2b, non-inferiority trial

著录项

相似文献

相关主题

期刊订阅